U.S. Healthtech Stock News

Micron’s latest quarterly results, with profits surging to almost 15 times the prior level, have put semiconductor and memory chip stocks back in the spotlight and reignited interest across global indices such as the Nasdaq and S&P 500. For investors watching how AI related demand, data centers, and supply and demand expectations ripple through this part of the market, the recent move in Micron and peers has created fresh questions about which stocks might benefit most from this renewed...

Nexstar Media Group (NasdaqGS:NXST) has agreed to acquire TEGNA, marking a major expansion of its local TV station portfolio. The company recently reported record quarterly net revenue alongside strong showings from NewsNation and The CW. NewsNation continues to gain traction as a cable news outlet, while The CW is moving closer to profitability with added sports programming. Nexstar Media Group enters this phase of expansion with its stock at $167.97 and a mixed recent performance, up 2.3%...

If you are wondering whether TD SYNNEX at US$283.22 is still a sensible entry or hold after a strong run, the key question is how its current price compares with a fair estimate of value. The stock has been relatively flat over the past week with a 0.2% decline, but that follows returns of 19.3% over 30 days, 84.6% year to date and 107.9% over 1 year, with a 224.6% return over 3 years and 148.0% over 5 years. Recent attention on TD SYNNEX has been driven less by a single headline event and...

Edgewell Personal Care (EPC) has drawn fresh attention after a sharp move in its share price over the past month, prompting investors to reassess the stock using its recent return profile and fundamentals. See our latest analysis for Edgewell Personal Care. The recent 50.51% 1 month share price return, alongside a 57.65% year to date share price gain, contrasts with a weaker 3 year total shareholder return that has declined 30.71%. This suggests short term momentum has picked up after a...

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 20% over the past year, with earnings expected to grow by 19% annually in the coming years. In this fluctuating environment, identifying stocks trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

The United States market has experienced a slight dip of 2.5% over the last week, yet it remains robust with a 20% increase over the past year and projected annual earnings growth of 19% in the coming years. In this context, growth companies with high insider ownership can be particularly appealing as they often align management's interests with those of shareholders, potentially positioning them well amidst fluctuating market conditions.

Over the last 7 days, the United States market has dropped 2.5%, but it remains up by 20% over the past year, with earnings expected to grow by 19% per annum in the coming years. In such a dynamic landscape, identifying stocks that combine value and growth potential can be particularly rewarding. Penny stocks, often representing smaller or newer companies, continue to offer intriguing opportunities for investors who focus on those with solid financial foundations and clear growth prospects.

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up 20% over the past year with earnings forecasted to grow by 19% annually. In this fluctuating environment, dividend stocks can offer a blend of income and potential growth, making them an attractive option for those looking to balance risk and reward in their investment portfolios.

LegalZoom.com (LZ) moved after fresh Prime Day data and declining Treasury yields shifted attention toward digital platforms, as record US online sales of $8.3 billion supported sentiment around companies tied to online economic activity and advertising. See our latest analysis for LegalZoom.com. Against the backdrop of Prime Day strength and lower Treasury yields, LegalZoom.com’s recent 1 day share price return of 3.35% and 7 day gain of 6.55% sit in contrast to a year to date share price...

Summit Therapeutics (SMMT) has drawn fresh attention after scrapping a proposed US$500 million underwritten public offering just a day after announcing it, a move linked to funding plans for lead drug ivonescimab. See our latest analysis for Summit Therapeutics. Against this backdrop, Summit Therapeutics’ share price return has fallen 14.26% over the past 30 days and 17.44% over 90 days. Its 1 year total shareholder return is down 33%, while the 3 year total shareholder return remains very...

In recent days, California Water Service Group reported stronger quarterly fundamentals, with revenue up 5.20% year over year and net profit rising very significantly by 69.72%, alongside a solid financial score of 7.21 within the Water & Related Utilities industry. At the same time, the company’s shares have been heavily owned by institutions at 92.30%, while price momentum and technical indicators currently signal range-bound but constructive trading conditions between identified support...

Earlier this week, Advanced Drainage Systems, Inc. was added to the Zacks Rank #5 (Strong Sell) list after its current-year earnings estimates were revised downward by 4.5% over the past 60 days, reflecting a weaker near-term earnings outlook. This downgrade comes on top of slowing revenue growth, declining earnings per share over the last two years, and a reduced return on invested capital, pointing to fewer high-return growth opportunities for the business. Next, we'll examine how the...

Carnival (CCL) opened Q2 2026 with revenue of US$6.7b and basic EPS of US$0.39, setting a clear marker for its latest earnings season update. The company reported quarterly revenue of US$6.3b in Q2 2025 and US$6.7b in Q2 2026, while basic EPS moved from US$0.43 to US$0.39 over the same period. Over the last twelve months, trailing basic EPS reached US$2.28 on revenue of US$27.3b. For investors, the combination of higher revenue over time and sustained profitability indicates that margins are...

S&P Global’s June PMI data points to continued expansion in US manufacturing and overall private sector activity. The same survey flags factory job cuts at the fastest pace since 2009 outside the Covid period. This mix of strong output readings and rising layoffs is drawing attention to how companies are managing costs against demand risks. S&P Global (NYSE:SPGI) sits at the center of how investors interpret signals like these, with its PMI surveys closely watched across markets. The stock...

Dyne Therapeutics (DYN) has moved squarely into focus after it appointed veteran biopharmaceutical executive Barry E. Greene as an independent board member and expanded its loan facility with Hercules Capital to support upcoming milestones. See our latest analysis for Dyne Therapeutics. For context, Dyne Therapeutics shares trade at $20.33, with a 30-day share price return of 17.04% and a year-to-date share price return of 9.89%. The 1-year total shareholder return of 95.11% reflects strong...

Apple’s decision to lift MacBook and iPad prices as memory and storage costs climb is rippling through the entire consumer electronics sector, not just Apple stock. Higher input costs, rising average selling prices and potential shifts in demand are now key pressure points for manufacturers and suppliers alike. For investors, that raises the question of which consumer electronics manufacturers could be positioned to benefit from this AI driven memory squeeze, and which might feel more of a...

Blackstone (NYSE:BX) plans to invest $30b in artificial intelligence focused data centers in Japan. The company expects to deploy this capital over the next three to five years. The commitment targets Japan's growing data center infrastructure to support AI workloads. For investors tracking Blackstone, this move comes as the stock trades around $112.99, with performance under pressure in the near term. Shares are down 9.6% over the past week, 4.7% over the past month, and 28.8% year to...

Investors may be wondering whether Axogen at US$42.52 still makes sense after such a strong run, or if the current price is getting ahead of itself. The stock has pulled back about 4.6% over the past week, after rising 4.0% over 30 days, 37.2% year to date, 314.8% over 1 year and 373.5% over 3 years, with a 96.8% return across 5 years. Recent coverage has focused on Axogen's share price performance and how the stock's sharp moves compare with broader medical equipment peers. This has put...

Recent Phase II results for Dabogratinib, Tyra Biosciences (TYRA) experimental therapy for non-muscle invasive bladder cancer, have drawn fresh attention to the company, its late stage pipeline, and how the stock reflects that potential. See our latest analysis for Tyra Biosciences. Tyra Biosciences share price has been volatile around the latest Dabogratinib update, with a 1-day share price return of 1.03% and 7-day share price return of 4.47%, set against a 30-day share price return that is...

Merck KGaA, traded in the U.S. via NYSE:MRK, agreed to acquire Bio-Techne Corporation in an US$11.3b transaction. The deal is structured to expand Merck KGaA’s reach in life sciences tools, diagnostics, and biomanufacturing support. The acquisition is intended to strengthen Merck KGaA’s position in the U.S. life sciences market and broaden its capabilities across the drug development value chain. For investors following Merck, this deal increases attention on the company’s life sciences...

Daktronics, Inc. recently reported fourth-quarter 2026 sales of US$208.61 million and net income of US$8.42 million, alongside full-year sales of US$838.71 million and net income of US$45.38 million, marking a shift from losses a year earlier. At the same time, Daktronics increased its equity buyback authorization to US$40 million, underlining management’s confidence in the company’s financial position and cash-generation profile. We’ll now look at how Daktronics’ move from loss to profit...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Himax...

MGM Resorts International and BetMGM recently renewed their multi‑year partnerships with Major League Baseball, keeping MGM as MLB’s exclusive Integrated Resort & Casino Partner and extending BetMGM’s marketing presence across MLB media, events, and co‑branded gaming products in the U.S. and Canada. This renewal strengthens MGM’s access to baseball fans through awards events in Las Vegas, team partnerships, and MLB‑themed betting and casino experiences, potentially deepening the link between...

STAAR Surgical recently filed a US$110.604 million shelf registration for 3,900,000 common shares and, following shareholder approval, expanded its Omnibus Equity Incentive Plan by the same number of shares. This combination of new capital-raising capacity and enlarged equity compensation pool, reflected in fresh grants to multiple directors, points to an emphasis on financial flexibility and alignment of leadership incentives with long-term company performance. We’ll now examine how STAAR...